Antithrombin Market analysis 2026

The increasing incidence of bleeding disorders, open-heart surgery, and extracorporeal circulation during hemodialysis is fueling the market for antithrombin. According to the Centers for Disease Control and Prevention (CDC), venous thromboembolism affects around 900,000 people each year in the US in 2015. In addition, 5 to 8% of the US population are at increased risk of thrombosis due to one of several genetic risk factors known as inherited thrombophilia.



Growth in the antithrombin market is also expected to be driven by advances in drug delivery technology and therapeutic drug portfolios. Alnylam Pharmaceuticals, Inc. developed Fitusiran (ALNAT3), a drug that targets antithrombin (AT) with RNA interference. Clinical trials on the drug (phase 2, phase 3) are in late stages to determine whether it will be effective in treating hemophilia and rare blood clotting disorders (RBD). ATryn Antithrombin (recombinant), Human Blood Donors, a generic product recently approved in the United States for the treatment of hereditary antithrombin deficiency, has also contributed to the growth of the antithrombin market. Growth in the global antithrombin market. Increasingly, antithrombin is being used in conjunction with heparin. Antithrombin's growth will be supported by Ely. Antithrombin products may be used in anticoagulation therapy in the future due to heparin resistance in cardiac surgery, for example.